2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Are the Primary Drivers Supporting the Market Growth of theIntermittent Claudication Market?

The escalating frequency of peripheral artery disease (PAD) is projected to propel the progression of the intermittent claudication market in the future. PAD is effectively a vascular disorder where the thinning of arteries diminishes blood supply to the limbs, inducing pain, numbness, and further complications. The surge in PAD cases can be attributed to elements such as an aging society, diabetes, smoking, high blood pressure, obesity, and inactive lifestyles. Peripheral artery disease hinders intermittent claudication by limiting the blood flow to leg muscles during physical activity, thus resulting in pain and cramping due to lack of oxygen. For instance, in June 2023, the American Heart Association Journals, a US-based peer-reviewed open-access scientific journal, reported that peripheral artery disease impacts 7-12 million individuals in the U.S. and 200 million worldwide. Hence, the surge in peripheral artery disease cases is steering the expansion of the intermittent claudication market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22021&type=smp

How Will the Growth Rate of theIntermittent Claudication Market Impact Industry Trends by 2034?

The market size for intermittent claudication has seen robust growth in the past few years. From 2024’s $12.81 billion, it is expected to grow to $13.64 billion in 2025, marking a compound annual growth rate (CAGR) of 6.5%. Factors contributing to the historical growth include an increase in peripheral artery disease, greater awareness of vascular illnesses, an aging population, improved diagnosis rates, and a rise in healthcare spending.

The market size of intermittent claudication is predicted to demonstrate substantial growth over the coming years, with an estimated value of $17.39 billion in 2029, reflecting a Compound Annual Growth Rate (CAGR) of 6.2%. This growth during the projection period can be accredited to factors such as the escalating incidences of diabetes, an upward trend in obesity rates, a surge in cardiovascular disease cases, increasing alcohol and tobacco use, along with a rise in healthcare expenditure. Among the prevailing trends within this predictive timeframe are advancements in the diagnosis of peripheral artery disease, the inclusion of wearable devices, incorporation of personalized medicine, a transition towards drug-eluting stents, and progress in stem cell therapy.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=22021

What Are the Latest Innovations Influencing theIntermittent Claudication Market?

Major players in the intermittent claudication market are shifting their attention to more advanced medication therapies such as RIPK1 inhibitors to enhance treatment solutions for patients plagued by peripheral artery disease (PAD) with intermittent claudication. The objective is to improve blood circulation, mitigate inflammation, and deter disease progression. RIPK1 inhibitors are specifically designed drugs that inhibit the activity of RIPK1 kinase, thereby reducing inflammation and cell death. For example, in August 2022, GenFleet, a biotech company based in China, gained US Food and Drug Administration’s (FDA) approval for their Phase II clinical trial of GFH312 – an innovative treatment for peripheral artery disease (PAD) with intermittent claudication (IC). This clinical trial will be a randomized, double-blinded, placebo-controlled study to be carried out across 15 research institutions. In previous preclinical studies, GFH312, a RIPK1 inhibitor, demonstrated potential in reining in the inflammatory response in animal models.

Who Are the Major Industry Players Accelerating Growth in theIntermittent Claudication Market?

Major companies operating in the intermittent claudication market are Pfizer Inc., Bristol Myers Squibb Company, AstraZeneca PLC, Novartis AG, GSK plc, Eli Lilly and Company, Merck KGaA, Teva Pharmaceutical, Otsuka Pharmaceutical Co. Ltd., Sanofi S.A., Bayer AG, Hikma Pharmaceuticals PLC, Dr. Reddy’s Laboratories, Pipelinepharma, Pharmaoffer, Alkem Laboratories, LGM Pharma, Aastrid Life Sciences Pvt. Ltd., Manus Aktteva Biopharma LLP, Enomark Pharma, Pharmacompass.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/intermittent-claudication-global-market-report

Which Primary Segments of the Intermittent Claudication Market Are Driving Growth and Industry Transformations?

The intermittent claudication market covered in this report is segmented –

1) By Type: Medication Therapies, Revascularization

2) By Route Of Administration: Parenteral Route, Oral Route, Other Routes Of Administration

3) By Application: Hospitals, Clinics, Home Healthcare, Other Applications

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Subsegments:

1) By Medication Therapies: Antiplatelet Agents, Vasodilators, Phosphodiesterase Inhibitors, Cilostazol, Pentoxifylline

2) By Revascularization: Angioplasty, Stenting, Bypass Surgery, Endarterectomy

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=22021&type=smp

Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theIntermittent Claudication Market?# Market?

North America was the largest region in the intermittent claudication market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the intermittent claudication market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Intermittent Claudication Market 2025, By The Business Research Company:

Intermittent Catheters Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/intermittent-catheters-global-market-report

Intermittent Pneumatic Compression (IPC) Devices Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/intermittent-pneumatic-compression-ipc-devices-global-market-report

Coronary Artery Disease Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/coronary-artery-disease-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: